# Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

> **NCT05907291** · PHASE2 · COMPLETED · sponsor: **Crinetics Pharmaceuticals Inc.** · enrollment: 38 (actual)

## Conditions studied

- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** atumelnant (CRN04894)

## Key facts

- **NCT ID:** NCT05907291
- **Lead sponsor:** Crinetics Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-03
- **Primary completion:** 2025-08-22
- **Final completion:** 2025-08-22
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05907291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05907291, "Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05907291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*